The Drug Is Recommended. The Test Isn’t Funded.

Earlier this year I wrote about the seven structural mistakes international diagnostics companies make when entering Canada. The third was assuming the drug funds the diagnostic — that a companion test rides its paired therapy into funded access the way it often does in the United States.

That article made the argument in the abstract. This one does not need to. Over the past eighteen months, molecular residual disease (MRD) testing has produced the clearest worked example of that mistake I have seen in more than two decades in this market, and it is documented in public files anyone can read.

Canada has now approved therapies that can only be prescribed to patients identified by an MRD test, funded those therapies through provincial drug programs, written MRD thresholds into reimbursement criteria — and, in the same period, published a government form naming two commercial MRD assays as ineligible for public funding.

This is not a story about weak science or slow committees. It is a story about two funding systems that were never designed to talk to each other, and about what happens to a diagnostics company that assumes they do.

Acute Myeloid Leukemia: The Committee Documented the Contradiction Itself

In its draft reimbursement recommendation for gilteritinib (Xospata, project PC0444-000), Canada’s Drug Agency expert review committee voted twelve to five to recommend reimbursement, with conditions, as post-transplant maintenance therapy for patients with measurable residual disease–positive, FLT3-ITD mutated AML.¹

Read the eligibility criterion carefully. It is not FLT3-ITD AML. It is MRD-positive FLT3-ITD AML. The committee restricted eligibility that way because that is where the pivotal evidence showed benefit. The MRD result is not supplementary information sitting alongside the funding decision. It is the gate.

In the same document, the committee stated that MRD testing for FLT3-ITD is not routinely available or funded in clinical practice in Canada. It noted that an ultra-high-sensitivity next-generation sequencing test with a threshold comparable to the one used in the pivotal trial is being validated at several Canadian centres, and it flagged the implementation questions that follow: how long until the test is available, who trains the personnel, who funds it, and how anyone navigates reimbursement for genetic and laboratory testing across thirteen jurisdictions.

Now add the economics, which are also in the file. At the submitted price, gilteritinib costs approximately $23,242 per patient per 28-day cycle. The agency’s own base case put the incremental cost against best supportive care at roughly $490,297 per patient, with an incremental cost-effectiveness ratio of about $277,163 per quality-adjusted life year.¹

Hold those two facts together, because this is the whole argument in miniature.

The MRD-positive restriction is central to making a half-million-dollar therapy defensible to a Canadian payer. The test is not a nice-to-have adjacent to the drug. The test is the cost-control instrument. It is what prevents the therapy from being given to a population in which it has not demonstrated benefit. And it is the unfunded half of the pair.

A US company reading this recommendation would reasonably conclude that Canada has just created demand for an ultra-sensitive FLT3-ITD MRD assay. That conclusion is correct about the clinical need and wrong about the commercial consequence. Nothing in a positive drug recommendation obliges any province to fund the test that operationalizes it. The drug flows through a pan-Canadian review into provincial formularies and cancer agency budgets. The test flows through hospital laboratory budgets, provincial molecular testing committees, and laboratory capacity planning. Different owners. Different cycles. No connecting mechanism.

A final recommendation was transmitted to the sponsor and drug plans on July 29, 2026. No final recommendation or review report had been publicly posted as of July 30, 2026, the research cut-off for this article; the draft reasons discussed above therefore reflect the public record reviewed for this analysis.¹

Acute Lymphoblastic Leukemia: The Regulator Wrote the Test Into the Label

If AML shows the funding gap, ALL shows something sharper: a Canadian regulator writing a diagnostic requirement directly into a drug’s indication, and a province operationalizing it, while the sensitivity of the required test drifts a full log behind clinical practice.

The Health Canada product monograph for blinatumomab indicates the drug for patients with Philadelphia chromosome–negative, CD19-positive B-cell precursor ALL in first or second hematologic complete remission with minimal residual disease greater than or equal to 0.1%. It goes on to specify that patients are to be selected for treatment based on detection of MRD as determined by an accredited laboratory using validated assay methods.²

That is a regulator writing an assay requirement into a label. Ontario’s New Drug Funding Program then operationalizes it: MRD-positive is defined as MRD detected at a level of at least 0.1%, or 10⁻³; patients who are MRD-negative or of unknown MRD status are not eligible.³

Here is where it becomes genuinely instructive. In a Canada’s Drug Agency review of blinatumomab, adult clinician groups stated that the 0.1% threshold is obsolete and that the current clinical standard is at least 0.01% — one order of magnitude more sensitive.⁴

So the funded eligibility criterion is pinned to a sensitivity the specialists who use it consider out of date. A patient measured at 0.05% is MRD-positive by contemporary practice and MRD-negative by the funding criterion. Whether that patient receives a funded therapy depends on which assay their centre runs and which threshold the paperwork uses.

For an MRD company, this is not a curiosity. It is a market-definition problem. Your addressable population in Canada is not defined by your assay’s limit of detection. It is defined by the threshold written into a funding criterion — and by whether provincial laboratories are equipped and funded to measure at that threshold consistently. Superior analytical sensitivity does not expand your Canadian market if the reimbursement architecture cannot recognize the result.

There is a further detail worth sitting with. Canadian children with Philadelphia-positive or ABL-class Philadelphia-like B-ALL can access clonoSEQ next-generation sequencing MRD testing — used in that trial for treatment allocation, at 10⁻⁶ rather than 10⁻⁵ sensitivity — through the Children’s Oncology Group AALL2131 study, with the C17 Council serving as Canadian regulatory sponsor and opening the trial at all sixteen Canadian pediatric oncology centres. Access to that assay is enabled by a research network’s support programme.⁵

Read that as a market signal rather than as an indictment. The most sensitive MRD technology reaches Canadian pediatric patients through a research funding pathway, because no routine funding pathway exists to carry it. If your Canadian revenue model depends on clinical adoption following trial exposure, understand what is actually carrying the cost today, and what happens when that support ends.

Solid Tumours: The Denial Is a Published Form

In hematology the gap is structural and largely unspoken. In solid tumours, Ontario has written it down.

Form 4521-84E, revised November 2025, governs the province’s Out-of-Country and Out-of-Province Prior Approval Program for laboratory and genetic testing services. It carries a list titled Ineligible Tests or Testing. The final entry reads: circulating tumour DNA for minimal residual disease monitoring in cancer patients, with two products named — Signatera and Guardant Reveal.⁶

I want to be precise about what this document is and is not, because the distinction matters commercially.

It is not a coverage determination in the American sense. It is the exclusion list for the mechanism Ontario uses to fund testing that cannot be performed in the province. That is the significant part. The out-of-country pathway is the natural route for a centralized American MRD service — the test genuinely is unavailable domestically, which is exactly the condition the programme exists to address. Ontario has closed that door specifically and named the products while doing it.

Meanwhile the tests are available. Signatera has been commercially distributed in Canada by LifeLabs since February 2023, with LifeLabs handling distribution and commercialization while Natera performs all testing and analysis. It is available in Ontario, British Columbia and Saskatchewan, and LifeLabs’ public store lists it at $2,000.00 to $4,500.00.⁷ Guardant expanded Canadian access to Guardant Reveal through a partnership with Bayshore HealthCare in 2025.⁸

So the Canadian position on solid-tumour MRD, as of today, is this: the tests are commercially available, publicly priced, marketed to patients and oncologists, formally excluded from the province’s out-of-country funding mechanism, and paid for privately. Three and a half years of commercial presence in the largest province have not produced public funding. They have produced a named exclusion.

If you are modelling Canadian entry through a distribution partner, this is the sequence to plan against. A private channel can be a legitimate bridge. It becomes a trap when nothing is being built underneath it — no Canadian utility data, no budget-impact case, no provincial laboratory relationship, no institutional pathway. Volume alone does not convert.

What the Evidence Actually Says

It would be convenient to argue that Canada is simply ignoring settled evidence. That argument is available, it would make a cleaner article, and it is not true. Companies that make it in front of Canadian decision-makers lose credibility they do not get back.

The DYNAMIC-III trial — an intergroup study run by the Australasian Gastro-Intestinal Trials Group and the Canadian Cancer Trials Group, presented at ESMO 2025 and published in Nature Medicine — is the most rigorous test to date of whether acting on a ctDNA result improves outcomes in stage III colon cancer.⁹

Its prognostic finding is unambiguous. Among 968 evaluable patients, 702 were ctDNA-negative after surgery, and three-year recurrence-free survival was 87% in that group against 49% in ctDNA-positive patients.⁹

The management findings are more complicated, and both directions matter.

De-escalation in ctDNA-negative patients cut oxaliplatin-based chemotherapy use from 88.6% to 34.8%, reduced grade 3 or higher adverse events of special interest from 10.6% to 6.2%, and reduced treatment-related hospitalization from 13.2% to 8.5%. But three-year recurrence-free survival was 85.3% with ctDNA guidance versus 88.1% with standard management — a difference of 2.8 percentage points, with a lower confidence bound of −8.0% against a pre-specified non-inferiority margin of 7.5%. Non-inferiority was not demonstrated. A pre-planned subgroup analysis suggested de-escalation may be non-inferior in clinically low-risk T1–3 N1 tumours, where the gap narrowed to 2.2 points.⁹

And in ctDNA-positive patients, treatment intensification did not improve recurrence-free survival.

Anyone building a Canadian value story should state this accurately, because the clinicians and committee members reading it already know. The honest position is that ctDNA is an excellent prognostic classifier whose optimal management application is still being defined, with the strongest signal in a toxicity-reduction use case in a defined low-risk subgroup.

That honest position is also strategically better, and this is the part most companies miss. A toxicity-reduction and treatment-sparing argument is the easiest kind of argument to make to a Canadian payer, because the value accrues to the same system that pays for the test. An earlier-detection argument asks a laboratory budget to spend money so that a drug budget, an imaging budget or a surgical budget may benefit later — three separate envelopes, none of which is the one being asked to pay.

Note also who ran the trial. Canada co-led the definitive study in this space. Canada helped generate the evidence but lacks a coherent cross-budget mechanism to translate it into routine, funded implementation. That is the actual problem, and more clinical evidence alone will not repair it.

The One Mechanism Now Being Built

There is a development that almost nobody outside Canada is tracking, and it is the most consequential thing happening in this market.

Canada’s Drug Agency is currently reviewing the evidence on minimal residual disease testing in multiple myeloma — project OP0561-000. Recommendations will be developed by the Health Technologies and Systems Expert Committee and will be non-binding. The agency describes the project explicitly as a proof-of-concept exercise, undertaken to explore whether, and how best, cancer biomarkers could be evaluated at a pan-Canadian level.¹⁰

That framing is the point. This is not primarily a review of myeloma MRD. It is an attempt to determine whether Canada should have a national process for evaluating cancer biomarkers at all — the mechanism whose absence produced every problem described above.

Any methodology that emerges is likely to influence how cancer diagnostics are assessed in this country: what evidence is requested, how clinical utility is defined for a test rather than a drug, how laboratory implementation is weighed, and how much any recommendation influences provincial decision-makers.

The agency’s call for industry input on this proof-of-concept closed on July 8, 2026.¹⁰ What matters now is not the submission window but the standard the completed consultation will produce.

Any company with an MRD asset and a Canadian ambition should be tracking this project closely — not to submit input that is no longer open, but to understand the standard being built before it is finished. The recommendations, once published, may be the closest thing Canada has to a rulebook for how cancer biomarker evidence gets judged, and the companies that read it first will be the ones prepared to meet it.

The Companies That Have Stopped Arguing and Started Re-Engineering

Everything above describes the same underlying constraint from three angles: Canadian public funding is structurally built around laboratories — not recurring per-test payments to foreign vendors.

Provincial funding attaches to laboratory operating budgets, equipment, reagents, staffing and accreditation. It does not attach easily to a per-test fee paid to a foreign laboratory for a service performed elsewhere. This is why hematologic MRD is comparatively well established in Canadian practice — those assays run inside provincial laboratories on instruments those laboratories already own — and why centralized solid-tumour MRD services remain outside the funded system despite stronger commercial evidence and far greater investment.

For most of the last five years the industry response to this has been to argue harder: more evidence, more guideline citations, more payer engagement. A different response is now visible, and it comes from the largest players in the field.

In 2026, Roche completed its acquisition of SAGA Diagnostics of Lund, Sweden, bringing the Pathlight platform into Foundation Medicine. The stated intent was not simply to add an assay to a menu. Roche described the objective as developing a decentralised MRD solution enabling patient access at global scale, combining Pathlight with its own AXELIOS sequencing and Digital LightCycler PCR platforms.¹¹ Foundation Medicine launched FoundationOne MRD in May 2026.¹²

Roche is not alone. Sysmex Inostics operates a CLIA laboratory in the United States while simultaneously distributing kit products across Europe and Asia-Pacific, and has introduced IVD-certified Plasma-SeqSensei kits into EMEA markets.¹³ Invivoscribe has for years sold CE-marked in vitro diagnostic MRD and clonality assays — LymphoTrack, and LeukoStrat assays for FLT3-ITD, NPM1 and KMT2A — designed to run on the customer’s own sequencers and digital PCR instruments, alongside its own reference laboratory service.¹⁴ Even among the centralized players, the direction is visible: Personalis obtained Class A CE-IVD marking under the European in vitro diagnostic regulation for its blood collection kits in June 2026.¹⁵

A Canadian example is worth noting, although it sits adjacent to MRD rather than inside it. Avitia, built in Montréal on assets acquired from Imagia Canexia Health following its 2023 bankruptcy, uses a decentralized model designed to place testing within accredited Canadian laboratory partners rather than a foreign centralized reference laboratory. Through Genoscience, it has expanded access across more than fifty Quebec collection and laboratory locations, with Calgary-based OncoHelix supporting testing and analysis. The pan-Canadian real-world dataset behind Follow It® included more than 4,100 patients referred through more than 150 institutions. Follow It® is used for treatment selection in advanced disease rather than postoperative residual-disease monitoring, but the deployment model is directly relevant to the argument above. Avitia has also launched a public campaign calling for liquid biopsy to be publicly reimbursed in Canada.¹⁶

I am not arguing that every MRD company should abandon centralized delivery. Centralization exists for real reasons: bioinformatics control, quality consistency, data assets, and the practical difficulty of distributing a bespoke tumour-informed workflow. For many assays it remains the correct model in the United States.

I am arguing something narrower and more useful. The delivery model is a market access decision, not merely an operational one — and in Canada it is the decision that determines whether a funding pathway exists at all. A company that has never modelled a licensed, in-province, kit-and-software deployment has not actually evaluated the Canadian market. It has evaluated one Canadian business model and concluded the market is difficult.

The strategic question is also not confined to Canada. The same logic — publicly funded laboratories, budget-based rather than fee-based reimbursement, national procurement, a preference for domestic capability — describes much of Europe, Australia and other single-payer systems. Canada is a comparatively small market that happens to be an accurate rehearsal for larger ones. A company that solves the in-province deployment question here has built something reusable.

If Canada Is on Your Expansion Slide

Recent transactions involving Natera’s acquisition of Foresight Diagnostics,¹⁷ Roche’s acquisition of SAGA,¹¹ and Tempus’s agreement to acquire Personalis¹⁸ suggest that commercial reach and deployment capability are becoming strategic drivers alongside science. Canada is a market where commercial reach is worth little without a funding pathway, and where a funding pathway cannot simply be bought.

Before committing budget, an executive team should be able to answer five questions with province-level specificity:

1. Is your Canadian revenue thesis private-pay, pharma-funded, or publicly funded? These require entirely different evidence packages, and only one of them scales.
2. Which province first, and on what basis? Not population. Governance structure, laboratory capacity, biomarker committee process, and whether your test links to an already-funded therapy.
3. Could your assay be deployed in-province as a licensed kit and software package? If you have never modelled it, you do not yet know what your Canadian market is worth.
4. Does your evidence package answer a Canadian question? Concordance against Canadian laboratory methods, budget impact within a laboratory envelope, and utility framed as system value rather than analytical superiority.
5. Are you tracking the pan-Canadian biomarker evaluation process and preparing your evidence strategy for the framework it produces?

Most companies I speak with can answer one or two of these. That is not a failure of diligence. It reflects the fact that the Canadian system publishes very little of what a company needs, and what it does publish sits in ministry forms, protocol documents, committee recommendations and laboratory requisitions rather than in market reports.

That gap is the work we do at SignalPoint Access Intelligence. Not market sizing. Structured provincial intelligence — decision gate mapping, funding pathway analysis, evidence-gap assessment, and deployment-model strategy — built for executive teams making capital allocation decisions about Canadian expansion.

If you are evaluating Canada for an MRD assay, or reassessing a Canadian position that has not converted, I am happy to give you a direct read on whether a viable pathway exists before you commit further budget.